ArticleScientific reports2026
Machine learning-driven dynamic prognosis for primary colorectal lymphoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary colorectal lymphoma (PCL) is a rare extranodal non-Hodgkin lymphoma that is often diagnosed at an advanced stage, resulting in poor prognosis and challenges in survival prediction. This study aimed to evaluate conditional survival (CS) outcomes and develop a dynamic CS-nomogram for individualized prognostic assessment. Data from the Surveillance, Epidemiology, and End Results (SEER) database (2004–2021) were used to identify 2,743 patients with PCL. CS analysis was integrated with a random survival forest (RSF) algorithm and multivariate Cox regression to construct a dynamic, individualized prognostic nomogram. Model performance was evaluated using calibration plots, time-dependent ROC curves, and decision curve analysis (DCA). Patients were stratified into risk groups according to nomogram-derived scores. Seven prognostic variables—age, histology, tumor stage, chemotherapy, tumor site, household income, and marital status—were identified through RSF. The nomogram demonstrated excellent calibration and consistent discriminatory performance, with AUC values remaining stable from 1 to 10 years in both the training and validation cohorts. Specifically, the 3-, 5-, and 10-year AUCs were 0.780, 0.789, and 0.812 in the training cohort, and 0.781, 0.780, and 0.808 in the validation cohort. CS analysis demonstrated progressively increasing survival probabilities with longer follow-up, reflecting the dynamic nature of prognosis. Risk stratification effectively distinguished groups with significantly different survival outcomes across a 10-year period. This RSF-based CS-nomogram provides accurate and dynamic survival predictions for PCL patients, outperforming traditional static models. Using a large population-based cohort, it supports personalized risk assessment and informed clinical decision-making. Future studies incorporating molecular profiling and prospective validation may further refine prognostic precision and guide individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.